BANK VONTOBEL/CALL/ELI LILLY & CO/640/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 02:02:00 2024-06-28 pm EDT | ||
| 26.4 EUR | +2.76% |
|
| Current month | +51.20% | ||
| 1 month | +60.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 26.4 | +2.76% |
| 24-06-27 | 25.69 | +1.42% |
| 24-06-26 | 25.33 | -1.32% |
| 24-06-25 | 25.67 | +2.48% |
| 24-06-24 | 25.05 | +4.68% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 02:02 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM3L3S |
| ISIN | DE000VM3L3S5 |
| Date issued | 2023-10-06 |
| Strike | 640 $ |
| Maturity | 2024-09-20 (83 Days) |
| Parity | 10 : 1 |
| Emission price | 3.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.58 € |
|---|---|
| Lowest since issue | 3.95 € |
| Spread | 0.02 € |
| Spread % | 0.08% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
